A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

NCT03863483 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Nonsquamous Non-Small Cell Lung Cancer

Interventions

DRUG: Sintilimab
DRUG: Docetaxel
DRUG: Pemetrexed
DRUG: Placebo

Sponsor

Xin-Hua Xu